Lentiviral particles allow easy gene delivery
Supplied ready to use
The Abingdon, UK-based firm supplies the new particles ready to use, eliminating the need for any lipids or transfection reagents. The company says these pre-made lentiviral particles are proven to deliver genes in a highly reproducible and controllable manner for the expression of more than 250 human proteins, mouse proteins, enzymes and fluorescent markers.
Using proprietary protocols based on co-expressed red fluorescent protein by a 2A peptide processing (SureTitre) or RSV promoter (Inducible system), these lentiviral particles enable real time monitoring of protein expression.
All AMSBIO lentiviral products are said to be easy and safe to use by simply adding the high titre particles (1 x 107 IFU/ml or higher) to cultured cells, and you will be able to confirm the specific target's expression under a fluorescent microscope after 48–72 hours.
AMSBIO lentiviral particles are packaged in culture medium with 10% FBS, in serum-free medium or concentrated in PBS for in vivo use.
You may also like
Manufacturing
Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part III)
Read moreThe third instalment from the CPHI Frankfurt show floor explores practical approaches and fresh perspectives on scale-up, tech transfer, and manufacturing innovation across the pharmaceutical sector
Trending Articles
You may also like
Manufacturing
Frontline innovation: dispatches from the show floor at CPHI Frankfurt (part II)
Industry leaders at CPHI Frankfurt are embracing emerging technologies — including automation, AI, advanced analytics and innovative manufacturing platforms — to drive efficiency, quality, scalability and sustainability in pharmaceutical production and development
Analysis
Anton Paar UK launches trade-in programme: Save up to 30% on new instruments
Anton Paar Ltd, a global leader in high-precision laboratory and process instrumentation, has launched a limited-time trade-in programme offering customers in the UK up to 30% off the price of new instruments across its comprehensive product portfolio*